82 related articles for article (PubMed ID: 23354013)
1. Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines.
Xiang J; Qiu W; Wang X; Zhou F; Wang Z; Liu S; Yue L
Oncol Rep; 2013 Apr; 29(4):1517-23. PubMed ID: 23354013
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ErbB-2 induces TFF3 downregulation in breast cancer cell lines.
Yue L; Xiang J; Shen Z; Wang Z; Yao Y; Zhou Q; Ding A; Qiu W
APMIS; 2014 Jul; 122(7):628-35. PubMed ID: 24164280
[TBL] [Abstract][Full Text] [Related]
3. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
5. Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators.
Conte N; Charafe-Jauffret E; Delaval B; Adélaïde J; Ginestier C; Geneix J; Isnardon D; Jacquemier J; Birnbaum D
Oncogene; 2002 Aug; 21(36):5619-30. PubMed ID: 12165861
[TBL] [Abstract][Full Text] [Related]
6. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
7. Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein.
Gabillard JC; Ulisse S; Baldini E; Sorrenti S; Cremet JY; Coccaro C; Prigent C; D'Armiento M; Arlot-Bonnemains Y
Biochem Biophys Res Commun; 2011 May; 408(4):647-53. PubMed ID: 21531210
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance.
Yue LU; Xiang JY; Sun P; Yao YS; Sun ZN; Liu XP; Wang HB; Shen Z; Yao RY
Anticancer Res; 2016 Mar; 36(3):1243-9. PubMed ID: 26977021
[TBL] [Abstract][Full Text] [Related]
10. Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis.
Cully M; Shiu J; Piekorz RP; Muller WJ; Done SJ; Mak TW
Cancer Res; 2005 Nov; 65(22):10363-70. PubMed ID: 16288026
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation.
Giani C; Casalini P; Pupa SM; De Vecchi R; Ardini E; Colnaghi MI; Giordano A; Ménard S
Oncogene; 1998 Jul; 17(4):425-32. PubMed ID: 9696035
[TBL] [Abstract][Full Text] [Related]
14. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.
Zhao YH; Zhou M; Liu H; Ding Y; Khong HT; Yu D; Fodstad O; Tan M
Oncogene; 2009 Oct; 28(42):3689-701. PubMed ID: 19668225
[TBL] [Abstract][Full Text] [Related]
16. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
17. Temporal and spatial expression of TACC1 in the mouse and human.
Lauffart B; Dimatteo A; Vaughan MM; Cincotta MA; Black JD; Still IH
Dev Dyn; 2006 Jun; 235(6):1638-47. PubMed ID: 16496324
[TBL] [Abstract][Full Text] [Related]
18. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
19. Cloning of TACC1, an embryonically expressed, potentially transforming coiled coil containing gene, from the 8p11 breast cancer amplicon.
Still IH; Hamilton M; Vince P; Wolfman A; Cowell JK
Oncogene; 1999 Jul; 18(27):4032-8. PubMed ID: 10435627
[TBL] [Abstract][Full Text] [Related]
20. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
